glp-1 receptor agonist market Size & Analysis, 2026-2033 GLP-1 Receptor Agonist Market Size,

ORLANDO, Fla

Evidence is emerging that glucagon-like peptide-1 (GLP-1) receptor agonists have anti-inflammatory and chondroprotective properties independent of their effects on weight loss

Combining exercise with GLP-1 RA liraglutide results in significant weight loss while preserving bone health in adults with obesity.

Due to a short plasma half-life of native GLP-1, several synthesized GLP-1 receptor agonists (RAs) were developed for type 2 diabetes mellitus (DM) treatment

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials